CPCB-RPE1 Implant

Retinal pigment epithelium (RPE) dysfunction and loss are a hallmark of  non-neovascular age-related macular degeneration (NNAMD). Without the  RPE, a majority of overlying photoreceptors ultimately degenerate,  leading to severe, progressive vision loss. Clinical and histological  studies suggest that RPE replacement strategies may delay disease  progression or restore vision. 

Regenerative Patch Technologies has developed composite subretinal implant, termed the  California Project to Cure Blindness-Retinal Pigment Epithelium 1  (CPCB-RPE1), consisting of a polarized monolayer of human embryonic stem  cell-derived RPE (hESC-RPE) on an ultrathin, synthetic parylene  substrate designed to mimic Bruch's membrane. 

A prospective, interventional, U.S. Food  and Drug Administration-cleared, phase 1/2a study assessing the safety and efficacy of CPCB-RPE1 in patients with non-neovascular age-related macular degeneration has now completed enrollment.